Page 14 - Immunotech Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

AIM ImmunoTech Receives Erasmus Medical Center Ethics Board Authorization for Phase 2 Study of Ampligen® for the Treatment of Locally Advanced Pancreatic Cancer

AIM ImmunoTech Receives Erasmus Medical Center Ethics Board Authorization for Phase 2 Study of Ampligen® for the Treatment of Locally Advanced Pancreatic Cancer
finanzen.at - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanzen.at Daily Mail and Mail on Sunday newspapers.

United statesErasmus medical center mc ethics committeeImmunotech incExchange commissionErasmus medical centerEthics committeePancreato biliary surgeonPrivate securities litigation reform act

Contrasting AIM ImmunoTech (NYSE:AIM) and Achilles Therapeutics (NASDAQ:ACHL)

Contrasting AIM ImmunoTech (NYSE:AIM) and Achilles Therapeutics (NASDAQ:ACHL)
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

United statesCity ofUnited kingdomImmunotech incHemispherx biopharma incAchilles therapeutics plcPolysciences incAmarex clinical researchPharmaceutics international incGet free reportAchilles therapeuticsAchilles therapeuticGiven achilles therapeuticTech incAlferonn injectionCagliari dipartimento

AIM ImmunoTech Announces that the First Subject is enrolled in the Phase 1b/2 Study Evaluating Ampligen in Combination with AstraZeneca s Imfinzi for the Treatment of Late-Stage Pancreatic Cancer

OCALA - AIM ImmunoTech Inc. today announced that the first subject has been enrolled at Erasmus Medical Center in a Phase 1b/2 clinical trial combining AIM s Ampligen with AstraZeneca s.

United statesThomask equelsJenene thomasDutch early access programImmunotech incExchange commissionErasmus medical centerMedical centerResponse evaluation criteriaPrivate securities litigation reform actNews publishing

AIM ImmunoTech Announces that the First Subject is Enrolled in the Phase 1b/2 Study Evaluating Ampligen® in Combination with AstraZeneca s Imfinzi® for the Treatment of Late-Stage Pancreatic Cancer | 22 01 24

AIM ImmunoTech Announces that the First Subject is Enrolled in the Phase 1b/2 Study Evaluating Ampligen® in Combination with AstraZeneca s Imfinzi® for the Treatment of Late-Stage Pancreatic Cancer | 22 01 24
finanzen.ch - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanzen.ch Daily Mail and Mail on Sunday newspapers.

United statesJenene thomasThomask equelsErasmus medical centerImmunotech incDutch early access programExchange commissionResponse evaluation criteriaPrivate securities litigation reform act

AIM ImmunoTech Announces Open Enrollment for Phase 1b/2 Study Evaluating Ampligen in Combination with AstraZeneca s Imfinzi for the Treatment of Pancreatic Cancer

OCALA - AIM ImmunoTech Inc. today announced that enrollment is open at Erasmus Medical Center in a Phase 1b/2 clinical trial combining AIM s Ampligen with AstraZeneca s anti-PD-L1 immune.

United statesThomask equelsTom equelsJenene thomasExchange commissionErasmus medical centerImmunotech incMedical centerCoordinating investigatorExecutive officerBig pharmaResponse evaluation criteriaPrivate securities litigation reform actNews publishing